证券日报网讯 8月20日晚间，采纳股份公告称，公司全资子公司采纳医疗近日收到国家知识产权局颁发 的三项实用新型专利证书，分别为"一种耐压防逆流输液管路""压力显示注射器"和"固定计量注射器"。 上述专利为公司自主研发，其所涉及技术均与公司主营业务产品技术相关，专利权自授权公告之日起生 效。上述专利的取得和运用，不会对公司短期的经营业绩构成重大影响，但有利于公司进一步完善知识 产权保护体系，形成持续创新机制，保持技术的领先地位，提升公司的核心竞争力。 （文章来源：证券日报） ...

Core Viewpoint - The stock price of Canar Medical Co., Ltd. closed at 24.22 yuan on August 20, 2025, reflecting a decrease of 0.14 yuan or 0.57% from the previous trading day [1] Company Overview - Canar Medical operates in the medical device sector, focusing on the research, production, and sales of medical products, veterinary products, and laboratory consumables [1] - In the 2024 annual report, medical products accounted for 51.23% of the company's revenue, while veterinary products made up 39.03% [1] Recent Developments - On August 20, 2025, Canar Medical announced that its wholly-owned subsidiary, Jiangsu Canar Medical Technology Co., Ltd., received three utility model patent certificates from the National Intellectual Property Administration. The patents include "a pressure-resistant anti-backflow infusion pipeline," "a pressure display syringe," and "a fixed measurement syringe," all of which are related to the company's main business products [1] Financial Performance - On August 20, 2025, the main funds experienced a net outflow of 716,700 yuan, with a cumulative net outflow of 4,222,500 yuan over the past five days [1]

Core Viewpoint - The company, Canar Medical Technology Co., Ltd., a wholly-owned subsidiary of Canar Co., has recently received three utility model patent certificates from the National Intellectual Property Administration of China, indicating a significant advancement in its product offerings [1] Group 1 - The patents awarded include "A Pressure-Resistant Anti-Backflow Infusion Pipeline," "Pressure Display Syringe," and "Fixed Measurement Syringe," showcasing the company's innovation in medical technology [1]